Compare DexCom, Inc. (DXCM) vs Corning Incorporated (GLW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Corning Incorporated — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while Corning Incorporated trades at $156.69 (market cap $131.65B). The key difference: Corning Incorporated is far larger — about 4.1× DexCom, Inc.'s market cap, and Corning Incorporated pays a 0.73% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Corning Incorporated for 36 Days on average.
| DXCM | GLW | |
|---|---|---|
Market Cap | $31.86B | $131.65B |
Volume | 3,607,070 | 8,992,522 |
Sector | Health | Technology |
52-Week High | $92.34 | $255.79 |
52-Week Low | $54.84 | $78.03 |
Typical Hold Time | 62 Days | 36 Days |
Enterprise Value | $31.32B | $138.52B |
Dividend Yield | — | 0.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.11, down 0.23% on the day, with a bearish technical signal but strong fundamental performance. The company reported Q2 2026 EPS of $0.70, beating expectations, and has shown consistent revenue growth, with 2025 revenue reaching $4.66 billion and net income of $836.3 million. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target. Recent news highlights growth opportunities in Type 2 diabetes care and key executive promotions.
The outlook for DXCM is positive due to robust earnings beats, expanding market opportunities, and strong institutional support. However, risks include competitive pressures, reimbursement challenges, and a high valuation with a P/E of 33.38. The stock presents a growth opportunity but requires monitoring of execution against these risks.
Corning (GLW) trades at $152.81, down 6.37% amid a bearish technical signal, though it recently secured a significant $3 billion fiber supply deal with AT&T. The company shows strong earnings momentum with three consecutive quarterly beats and improved 2025 financials, including revenue growth to $15.63B and net income of $1.60B. Valuation ratios remain elevated with a P/E of 70.43, while analyst consensus is bullish with a $171.25 price target.
The outlook is mixed: the AT&T deal and earnings strength support growth, but high valuation and a bearish technical picture pose risks. Investors should weigh the company's positioning in AI-driven infrastructure against potential volatility from patent litigation and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Corning Incorporated
Corning Inc is a leader in materials science, specializing in the production of glass, ceramics and optical fiber. The firm supplies its products for a wide range of applications, from flat-panel displays in televisions to gasoline particulate filters in automobiles to optical fiber for broadband access, with a leading share in many of its end markets.
Read more on GLW →
